Monograph Details
|
|
Gastrointestinal Tract
> Hyperacidity, GERD, and ulcers
|
|
AXID ORAL SOLUTION |
| Manufacturer |
|
Braintree Laboratories, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
H2 blocker. |
| Generic Name |
|
Nizatidine 15mg/mL; bubble gum flavor. |
| Also |
|
• AXID
|
| Indications |
|
Active duodenal ulcer. Maintenance of healed duodenal ulcer. Benign gastric ulcer. Gastroesophageal reflux disease (GERD): including heartburn and erosive and ulcerative esophagitis. |
| Children |
|
Not recommended. |
| Adults |
|
Active duodenal or benign gastric ulcer: 300mg daily at bedtime or 150mg twice daily, both for up to 8 weeks. Maintenance: 150mg daily at bedtime. GERD: 150mg twice daily for up to 12 weeks. Renal impairment: see literature. |
| Precautions |
|
Rule out malignant gastric ulceration. Renal insufficiency, reduce dose (see literature). Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended. |
| Interactions |
|
May elevate serum salicylate levels in high-dose aspirin patients. |
| Adverse Reactions |
|
Headache, anemia, diarrhea, dizziness, sweating, rhinitis, urticaria. |
| How Supplied |
Caps 150mg—60, 500
300mg—30
Soln—480mL |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
